| 摘要 |
PURPOSE: To obtain a new thrombolytic composition manifesting excellent synergism and having activities for more rapidly dissolving a thrombus by combining a modified t-PA (tissue-type plasminogen activator) as a major component with a normal human t-PA, and streptokinase or human urokinase as a minor component. CONSTITUTION: This thrombolytic composition comprises in combination a modified t-PA having an extended biologdool half-life as a major component, and a smaller amount of a normal human t-PA, streptokinase or a human urokinase as a minor component. The use together with the minor component can remove a lag phase of the thrombolytic activities and enhance the activities to a level of the normal t-PA. The amount of the minor component is preferably <=30wt.% based on the total amount of the both components. The treatment of thrombosis is performed by administrating <=30mg before minor component to the thrombosis patient by an initial injection and thereafter an effective amount of the modified t-PA by the second injection or infusion to the same patient.
|
